Related Experiment Video
Updated: Dec 11, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical
Marcello De Angelis1, Maria Petracca1, Roberta Lanzillo1
1Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Via Sergio Pansini 5, 80131 Naples, Italy.
Background:
The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels.
Implications:
Benign COVID-19 clinical course and anti-SARS-CoV-2 antibody production can occur in MS patients with lymphopenia, suggesting the possibility to respond to COVID-19 vaccination, once available, in this vulnerable population.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Therapeutic Drug Monitoring: Overview and Classification
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

